Stocks Health care LXRX
NASDAQ · Health careLexicon Pharmaceuticals, Inc. (LXRX)
Lexicon Pharmaceuticals, Inc. brought in $38.5M of revenue over the twelve months to September 30, 2026, down 45.6% from a year earlier. It posted a net loss of $62.4M. In fiscal 2025 capital spending exceeded operating cash flow by $67.9M. At September 30, 2026 it held $44.1M in cash against $51.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Lexicon Pharmaceuticals, Inc.
- Net worth
- Lexicon Pharmaceuticals, Inc. has a market value (market cap) of $809.8M at the latest share price, and shareholders' equity of $163.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $49.8M (+60.2% year on year), with a net loss of $50.3M. Over the 12 months to September 30, 2026: revenue $38.5M, net loss $62.4M.
- Cash flow
- In fiscal 2025 operations used $67.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lexicon Pharmaceuticals, Inc.'s next report is expected around January 28, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Lexicon Pharmaceuticals, Inc. does
Lexicon Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LXRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $49.8M | -$50.3M | -$0.14 | -$67.9M |
| 2024 | $31.1M | -$200.4M | -$0.63 | -$179.8M |
| 2023 | $1.2M | -$177.1M | -$0.80 | -$162.4M |
| 2022 | $139K | -$101.9M | -$0.62 | -$90.2M |
| 2021 | $298K | -$87.8M | -$0.60 | -$88.2M |
| 2019 | $24M | -$58.6M | -$0.53 | -$143.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LXRX ranks in Health care
Latest SEC filings
What Lexicon Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 21% to $11.3M versus the same quarter last year; diluted EPS -$0.03 versus -$0.04.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026
- August 6, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 98% to $692K versus the same quarter last year; diluted EPS -$0.07 versus $0.01.
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- May 8, 2026Activist stake changed SCHEDULE 13D/A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 1,572% to $21.1M versus the same quarter last year; diluted EPS $0.00 versus -$0.07.
Insider trades
What the people running Lexicon Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $50K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Exton MichaelChief Executive Officer, Director | Bought | 30,064 | $50K |
| June 3, 2026 | Debbane RaymondDirector | Exercised options | 89,312 | - |
| June 3, 2026 | Amouyal PhilippeDirector | Exercised options | 89,312 | - |
| June 3, 2026 | Barker Sam LDirector | Exercised options | 89,312 | - |
| June 3, 2026 | Cheung IvanDirector | Exercised options | 89,312 | - |
| June 3, 2026 | Sobecki Christopher JDirector | Exercised options | 89,312 | - |
| June 3, 2026 | Sullivan Diane E.Director | Exercised options | 89,312 | - |
| June 3, 2026 | Swain Judith LDirector | Exercised options | 89,312 | - |
Who owns LXRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Artal Participations S.a r.l.13D, may seek influence with 17 related filers | 39.4% | May 8, 2026 |
| Artal International S.C.A.13D, may seek influence with 14 related filers | 37.7% | July 29, 2024 |
| Artal Participations S.à r.l.13D, may seek influence with 15 related filers | 37.7% | December 9, 2024 |
| Fmr LLC13G, passive with 1 related filers | 11.7% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 149 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Artal Group S.A. | 175,156,062 | +20,421,735 |
| Fmr LLC | 51,782,045 | +6,725,707 |
| Siren, L.L.C. | 44,303,518 | 0 |
| Sessa Capital IM, L.P. | 18,960,836 | +1,047,875 |
| BlackRock, Inc. | 17,348,741 | +14,026,522 |
| Vanguard Capital Management LLC | 9,901,208 | +382,041 |
| Point72 Asset Management, L.P. | 8,251,325 | +436,719 |
| Geode Capital Management, LLC | 6,244,372 | +3,075,261 |
| State Street Corp | 4,917,769 | +3,953,731 |
| Vanguard Portfolio Management LLC | 2,357,749 | +1,811,149 |
| Northern Trust Corp | 1,968,619 | +1,473,953 |
| Charles Schwab Investment Management Inc | 1,956,775 | +645,477 |
| Vanguard Fiduciary Trust Co | 1,634,571 | +302,287 |
| Citadel Advisors LLC | 1,601,182 | +506,281 |
| Ishara Investments LP | 1,271,000 | +369,000 |
| Millennium Management LLC | 1,134,229 | -3,810,502 |
| Renaissance Technologies LLC | 1,127,000 | -473,500 |
| Mackenzie Financial Corp | 963,354 | +190,677 |
| ADAR1 Capital Management, LLC | 750,000 | 0 |
| Susquehanna International Group, Llp | 696,776 | -1,424,388 |
Insiders
17 insiders reported holding 182,476,250 shares in total, about $332.1M at the last price.
| Holder | Shares |
|---|---|
| Artal Participations S.a r.l.Director, 10% owner | 175,564,497175,564,497 held indirectly |
| Debbane RaymondDirector | 1,995,498 |
| Invus Global Management, LLCDirector, 10% owner | 1,905,6071,905,607 held indirectly |
| Crum Brian TSVP, General Counsel & Secr. | 428,802 |
| Amouyal PhilippeDirector | 374,486 |
| Exton MichaelChief Executive Officer, Director | 328,496 |
| Granowitz Craig BSVP, Chief Medical Officer | 323,430 |
| Sobecki Christopher JDirector | 293,177 |
| McDermott WendySVP, Human Resources | 277,945 |
| Barker Sam LDirector | 213,771 |
Questions about LXRX
What does Lexicon Pharmaceuticals, Inc. do?
Lexicon Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as LXRX. Its shares trade on NASDAQ under the ticker LXRX.
What is Lexicon Pharmaceuticals, Inc.'s net worth?
Lexicon Pharmaceuticals, Inc. has a market value (market cap) of $809.8M at the latest share price, and shareholders' equity of $163.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lexicon Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $62.4M on revenue of $38.5M.
How much revenue does Lexicon Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Lexicon Pharmaceuticals, Inc. reported revenue of $38.5M. That is 45.6% less than a year earlier.
When did Lexicon Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is Lexicon Pharmaceuticals, Inc.'s next earnings report?
Lexicon Pharmaceuticals, Inc.'s next report is expected around January 28, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LXRX with
Follow LXRX
Get an email when Lexicon Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lexicon Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.